Anti-inflammatory reliever therapy (AIR) for asthma
(2024)
Journal Article
Levy, M. L., & Crooks, M. G. (2024). Anti-inflammatory reliever therapy (AIR) for asthma. ERJ Open Research, 10(5), Article 00494-2024. https://doi.org/10.1183/23120541.00494-2024
All Outputs (64)
Breathlessness without borders: a call to action for global breathlessness research (2024)
Journal Article
Clark, J. D., Binnie, K., Bond, M., Crooks, M., Currow, D. C., Curry, J., Elsey, H., Habib, M., Hutchinson, A., Soyiri, I., Johnson, M. J., Nair, S., Rao, S., Siqueira-Filha, N., Spathis, A., & Williams, S. (2024). Breathlessness without borders: a call to action for global breathlessness research. NPJ Primary Care Respiratory Medicine, 34(1), Article 26. https://doi.org/10.1038/s41533-024-00384-9It is likely that the burden of breathlessness in low and middle-income countries (LMICs) is much higher than has been estimated using calculations of disease burden and expected prevalence of the symptom. However, most breathlessness research has be... Read More about Breathlessness without borders: a call to action for global breathlessness research.
Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England (2024)
Journal Article
Wang, H. I., Doran, T., Crooks, M. G., Khunti, K., Heightman, M., Gonzalez-Izquierdo, A., Qummer Ul Arfeen, M., Loveless, A., Banerjee, A., & Van Der Feltz-Cornelis, C. (2024). Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. Journal of Infection, 89(4), Article 106235. https://doi.org/10.1016/j.jinf.2024.106235Objectives: This study examines clinically confirmed long-COVID symptoms and diagnosis among individuals with COVID in England, aiming to understand prevalence and associated risk factors using electronic health records. To further understand long CO... Read More about Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.
Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0) (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0). NPJ Primary Care Respiratory Medicine, 34(1), Article 19. https://doi.org/10.1038/s41533-024-00376-9Correction to: npj Primary Care Respiratory Medicine34, 6 (2024) https://doi.org/10.1038/s41533-024-00363-0, published online 29 April 2024 In this article the Table 2 columns were incorrectly structured. The original article has been corrected.
Integrated care policy recommendations for complex multisystem long term conditions and long COVID (2024)
Journal Article
van der Feltz-Cornelis, C. M., Sweetman, J., Turk, F., Allsopp, G., Gabbay, M., Khunti, K., Williams, N., Montgomery, H., Heightman, M., Lip, G. Y., Crooks, M. G., Strain, W. D., Loveless, A., Hishmeh, L., Smith, N., & Banerjee, A. (2024). Integrated care policy recommendations for complex multisystem long term conditions and long COVID. Scientific reports, 14(1), Article 13634. https://doi.org/10.1038/s41598-024-64060-1The importance of integrated care for complex, multiple long term conditions was acknowledged before the COVID pandemic but remained a challenge. The pandemic and consequent development of Long COVID required rapid adaptation of health services to ad... Read More about Integrated care policy recommendations for complex multisystem long term conditions and long COVID.
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD (2024)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Newall, C., Mankowski, M., Crooks, M. G., Singh, D., Chaudhuri, R., Leaker, B., Lunn, K., Reynolds, S., Dudley, S., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2024). Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD. Respiratory Research, 25(1), Article 228. https://doi.org/10.1186/s12931-024-02854-7Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. This exploratory study aimed to demonst... Read More about Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.
Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites. NPJ Primary Care Respiratory Medicine, 34(1), Article 6. https://doi.org/10.1038/s41533-024-00363-0Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA... Read More about Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.
Accelarated immune ageing is associated with COVID-19 disease severity (2024)
Journal Article
Lord, J. M., Veenith, T., Sullivan, J., Sharma-Oates, A., Richter, A. G., Greening, N. J., McAuley, H. J., Evans, R. A., Moss, P., Moore, S. C., Turtle, L., Gautam, N., Gilani, A., Bajaj, M., Wain, L. V., Brightling, C., Raman, B., Marks, M., Singapuri, A., Elneima, O., …on behalf of the PHOSP-COVID Study collaborative group. (2024). Accelarated immune ageing is associated with COVID-19 disease severity. Immunity and Ageing, 21(1), Article 6. https://doi.org/10.1186/s12979-023-00406-zBackground: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and ac... Read More about Accelarated immune ageing is associated with COVID-19 disease severity.
Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis (2024)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Wright, C., Flockton, R., James, S. R., Crooks, M. G., Kaye, P. M., & Hart, S. P. (2024). Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis. Lung, https://doi.org/10.1007/s00408-024-00743-wIntroduction: In sarcoidosis granulomas, monocyte-derived macrophages are activated by pro-inflammatory cytokines including TNF and IL-6. Current drug treatment for sarcoidosis aims to suppress inflammation but disabling side effects can ensue. The m... Read More about Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis.
The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies (2024)
Journal Article
Sykes, D. L., Mason, P., Rahunathan, N., Hart, S. P., Morice, A. H., & Crooks, M. G. (2024). The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies. Lung, https://doi.org/10.1007/s00408-024-00729-8Introduction: Azithromycin is an effective treatment for various respiratory conditions but its effect on cough is poorly understood. We synthesised data from randomised controlled trials (RCTs) and noncomparative studies (NCT) examining its effect o... Read More about The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies.
Long COVID and cardiovascular disease: a prospective cohort study (2024)
Journal Article
Lawson, C. A., Moss, A. J., Arnold, J. R., Bagot, C., Banerjee, A., Berry, C., Greenwood, J., Hughes, A. D., Khunti, K., Mills, N. L., Neubauer, S., Raman, B., Sattar, N., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H. J., Shikotra, A., Singapuri, A., Sereno, M., …on behalf of the PHOSP-COVID Study Collaborative Group. (2024). Long COVID and cardiovascular disease: a prospective cohort study. Open heart, 11(1), Article e002662. https://doi.org/10.1136/openhrt-2024-002662Background Pre-existing cardiovascular disease (CVD) or cardiovascular risk factors have been associated with an increased risk of complications following hospitalisation with COVID-19, but their impact on the rate of recovery following discharge is... Read More about Long COVID and cardiovascular disease: a prospective cohort study.
Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective (2023)
Journal Article
Turk, F., Sweetman, J., Allsopp, G., Crooks, M., Cuthbertson, D. J., Gabbay, M., Hishmeh, L., Lip, G. Y., Strain, W. D., Williams, N., Wootton, D., Banerjee, A., & van der Feltz-Cornelis, C. (2023). Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective. Journal of Evidence-Based Medicine, 16(4), 435-437. https://doi.org/10.1111/jebm.12563
Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study (2023)
Journal Article
Sykes, D. L., Van der Feltz-Cornelis, C. M., Holdsworth, L., Hart, S. P., O'Halloran, J., Holding, S., & Crooks, M. G. (2023). Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study. Immunity, Inflammation and Disease, 11(10), Article e1052. https://doi.org/10.1002/iid3.1052Introduction: Long-COVID is a heterogeneous condition with a litany of physical and neuropsychiatric presentations and its pathophysiology remains unclear. Little is known about the association between inflammatory biomarkers, such as interleukin-6 (... Read More about Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study.
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 (2023)
Journal Article
Wilkinson, T., De Soyza, A., Carroll, M., Chalmers, J. D., Crooks, M. G., Griffiths, G., Shankar-Hari, M., Ho, L. P., Horsley, A., Kell, C., Lara, B., Mishra, B., Moate, R., Page, C., Pandya, H., Raw, J., Reid, F., Saralaya, D., Scott, I. C., Siddiqui, S., …on behalf of The ACCORD Collaborative Group. (2023). A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ Open Research, 9(5), Article 00249-2023. https://doi.org/10.1183/23120541.00249-2023Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving ou... Read More about A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) (2023)
Journal Article
Alwan, N. A., Clutterbuck, D., Pantelic, M., Hayer, J., Fisher, L., Hishmeh, L., Heightman, M., Allsopp, G., Wootton, D., Khan, A., Hastie, C., Jackson, M., Rayner, C., Brown, D., Parrett, E., Jones, G., Smith, K., Clarke, R., McFarland, S., Gabbay, M., …Cleary, N. (2023). Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways). PLoS ONE, 18(7 July), Article e0284297. https://doi.org/10.1371/journal.pone.0284297Background and aim Long Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the wor... Read More about Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways).
Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site (2023)
Journal Article
Crooks, M. G., Crowther, L., Cummings, H., Cohen, J., Huang, C., Pitel, L., Pearson, M., Morice, A., Turgoose, J., Faruqi, S., Watt, M., Morris, T., & Xu, Y. (2023). Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site. ERJ Open Research, 9(3), Article 00685-2022. https://doi.org/10.1183/23120541.00685-2022Aim: Short-acting β2-agonist (SABA) overuse adversely impacts asthma-related outcomes and the environment. The SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) programme aims to reduce SABA overuse through supported implementatio... Read More about Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.
Designing an intervention to help the quitters quit: A qualitative, intervention co-design study (2023)
Journal Article
Dyson, J., Skinner, J., Crick, J., & Crooks, M. G. (2023). Designing an intervention to help the quitters quit: A qualitative, intervention co-design study. PEC Innovation, 2, Article 100141. https://doi.org/10.1016/j.pecinn.2023.100141Objective: E-cigarettes are increasingly being provided by publicly funded stop smoking services. Our objectives were to understand the challenges and establish the means by which services could best support the use and subsequent discontinuation of... Read More about Designing an intervention to help the quitters quit: A qualitative, intervention co-design study.
Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study (2023)
Journal Article
Killingback, C., Thompson, M., Nettleton, M., Hyde, L., Marshall, P., Shepherdson, J., …Simpson, A. J. (2023). Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study. Disability and Rehabilitation, https://doi.org/10.1080/09638288.2022.2159075Purpose: The aim of this qualitative study was to explore the views of participants of a group-based, supervised, telerehabilitation programme, following discharge from hospital with Covid-19. This study was part of a single-centre, fast-track (wait-... Read More about Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study.
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study (2023)
Journal Article
Dennis, A., Cuthbertson, D. J., Wootton, D., Crooks, M., Gabbay, M., Eichert, N., Mouchti, S., Pansini, M., Roca-Fernandez, A., Thomaides-Brears, H., Kelly, M., Robson, M., Hishmeh, L., Attree, E., Heightman, M., Banerjee, R., & Banerjee, A. (2023). Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine, 116(3), 97-112. https://doi.org/10.1177/01410768231154703Objectives: To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation. Design: Prospective cohort study. Participants: Individuals. Methods: In indiv... Read More about Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study.
STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol (2023)
Journal Article
Forshaw, D., Wall, E. C., Prescott, G., Dehbi, H. M., Green, A., Attree, E., Hismeh, L., Strain, W. D., Crooks, M. G., Watkins, C., Robson, C., Banerjee, R., Lorgelly, P., Heightman, M., & Banerjee, A. (2023). STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol. PLoS ONE, 18(2), Article e0272472. https://doi.org/10.1371/journal.pone.0272472INTRODUCTION: Long COVID (LC), the persistent symptoms ≥12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are ur... Read More about STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol.